| Chapter title |
Adverse Events in Cancer Immunotherapy
|
|---|---|
| Chapter number | 8 |
| Book title |
Immunotherapy
|
| Published in |
Advances in experimental medicine and biology, March 2017
|
| DOI | 10.1007/978-3-319-53156-4_8 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-953155-7, 978-3-31-953156-4
|
| Authors |
Abdel-Wahab, Noha, Alshawa, Anas, Suarez-Almazor, Maria E., Noha Abdel-Wahab, Anas Alshawa, Maria E. Suarez-Almazor |
| Abstract |
Cancer immunotherapy has resulted in durable responses in patients with metastatic disease, unseen with traditional chemotherapy. Several therapies have been approved by the Food and Drug Administration for the treatment of various cancers, including: immune checkpoint inhibitors, cytokines - interleukin 2 (IL-2) and interferon alpha (IFN), and the cancer vaccine sipuleucel-T. These therapies upregulate the immune system to enhance antitumor responses. As a consequence, they can cause inflammatory and immune-related adverse events that can affect one or more organs, can be serious, and on occasion lifethreatening. The management of these adverse events is complex, and requires a multidisciplinary approach involving not only oncologists, but also other internal medicine specialists, to ensure prompt diagnosis and optimal management of these complications. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 75 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 19% |
| Student > Ph. D. Student | 12 | 16% |
| Student > Master | 9 | 12% |
| Other | 5 | 7% |
| Student > Doctoral Student | 5 | 7% |
| Other | 12 | 16% |
| Unknown | 18 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 36% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Agricultural and Biological Sciences | 5 | 7% |
| Nursing and Health Professions | 3 | 4% |
| Neuroscience | 3 | 4% |
| Other | 6 | 8% |
| Unknown | 24 | 32% |